ID   DUSTY_HUMAN             Reviewed;         929 AA.
AC   Q6XUX3; B7ZL64; O75060; Q17R94; Q5RKT0; Q6IN87; Q6P997; Q86Y03; Q9P1S5;
DT   02-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   12-OCT-2022, entry version 158.
DE   RecName: Full=Dual serine/threonine and tyrosine protein kinase;
DE            EC=2.7.12.1;
DE   AltName: Full=Dusty protein kinase;
DE            Short=Dusty PK;
DE   AltName: Full=RIP-homologous kinase;
DE   AltName: Full=Receptor-interacting serine/threonine-protein kinase 5;
DE   AltName: Full=Sugen kinase 496;
DE            Short=SgK496;
GN   Name=DSTYK; Synonyms=KIAA0472, RIP5, RIPK5, SGK496; ORFNames=HDCMD38P;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=17123648; DOI=10.1016/j.bbaexp.2006.10.004;
RA   Peng J., Dong W., Chen Y., Mo R., Cheng J.-F., Hui C.-C., Mohandas N.,
RA   Huang C.-H.;
RT   "Dusty protein kinases: primary structure, gene evolution, tissue specific
RT   expression and unique features of the catalytic domain.";
RL   Biochim. Biophys. Acta 1759:562-572(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Dendritic cell;
RA   Zhao Z., Huang X., Li N., Zhu X., Cao X.;
RT   "A novel gene from human dendritic cell.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Brain, Eye, Muscle, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 565-929 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455484; DOI=10.1093/dnares/4.5.345;
RA   Seki N., Ohira M., Nagase T., Ishikawa K., Miyajima N., Nakajima D.,
RA   Nomura N., Ohara O.;
RT   "Characterization of cDNA clones in size-fractionated cDNA libraries from
RT   human brain.";
RL   DNA Res. 4:345-349(1997).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-681.
RX   PubMed=15178406; DOI=10.1016/j.bbrc.2004.04.194;
RA   Zha J., Zhou Q., Xu L.G., Chen D., Li L., Zhai Z., Shu H.B.;
RT   "RIP5 is a RIP-homologous inducer of cell death.";
RL   Biochem. Biophys. Res. Commun. 319:298-303(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [9]
RP   INVOLVEMENT IN CAKUT1, VARIANTS CAKUT1 GLN-29; GLY-200 AND LEU-843,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=23862974; DOI=10.1056/nejmoa1214479;
RA   Sanna-Cherchi S., Sampogna R.V., Papeta N., Burgess K.E., Nees S.N.,
RA   Perry B.J., Choi M., Bodria M., Liu Y., Weng P.L., Lozanovski V.J.,
RA   Verbitsky M., Lugani F., Sterken R., Paragas N., Caridi G., Carrea A.,
RA   Dagnino M., Materna-Kiryluk A., Santamaria G., Murtas C.,
RA   Ristoska-Bojkovska N., Izzi C., Kacak N., Bianco B., Giberti S.,
RA   Gigante M., Piaggio G., Gesualdo L., Kosuljandic Vukic D., Vukojevic K.,
RA   Saraga-Babic M., Saraga M., Gucev Z., Allegri L., Latos-Bielenska A.,
RA   Casu D., State M., Scolari F., Ravazzolo R., Kiryluk K., Al-Awqati Q.,
RA   D'Agati V.D., Drummond I.A., Tasic V., Lifton R.P., Ghiggeri G.M.,
RA   Gharavi A.G.;
RT   "Mutations in DSTYK and dominant urinary tract malformations.";
RL   N. Engl. J. Med. 369:621-629(2013).
RN   [10]
RP   FUNCTION, TISSUE SPECIFICITY, AND INVOLVEMENT IN SPG23.
RX   PubMed=28157540; DOI=10.1016/j.ajhg.2017.01.014;
RA   Lee J.Y., Hsu C.K., Michael M., Nanda A., Liu L., McMillan J.R.,
RA   Pourreyron C., Takeichi T., Tolar J., Reid E., Hayday T., Blumen S.C.,
RA   Abu-Mouch S., Straussberg R., Basel-Vanagaite L., Barhum Y., Zouabi Y.,
RA   Al-Ajmi H., Huang H.Y., Lin T.C., Akiyama M., Lee J.Y., McLean W.H.,
RA   Simpson M.A., Parsons M., McGrath J.A.;
RT   "Large intragenic deletion in DSTYK underlies autosomal-recessive
RT   complicated spastic paraparesis, SPG23.";
RL   Am. J. Hum. Genet. 100:364-370(2017).
CC   -!- FUNCTION: Acts as a positive regulator of ERK phosphorylation
CC       downstream of fibroblast growth factor-receptor activation
CC       (PubMed:23862974, PubMed:28157540). Involved in the regulation of both
CC       caspase-dependent apoptosis and caspase-independent cell death
CC       (PubMed:15178406). In the skin, it plays a predominant role in
CC       suppressing caspase-dependent apoptosis in response to UV stress in a
CC       range of dermal cell types (PubMed:28157540).
CC       {ECO:0000269|PubMed:15178406, ECO:0000269|PubMed:23862974,
CC       ECO:0000269|PubMed:28157540}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17123648,
CC       ECO:0000269|PubMed:23862974}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q6XUX1}. Apical cell membrane
CC       {ECO:0000269|PubMed:23862974}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:23862974}. Cell junction
CC       {ECO:0000250|UniProtKB:Q6XUX1}. Note=Detected at apical cell-cell
CC       junctions. Colocalized with FGF receptors to the cell membrane (By
CC       similarity). Detected in basolateral and apical membranes of all
CC       tubular epithelia. {ECO:0000250|UniProtKB:Q6XUX1,
CC       ECO:0000269|PubMed:23862974}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q6XUX3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6XUX3-2; Sequence=VSP_018034;
CC       Name=3;
CC         IsoId=Q6XUX3-3; Sequence=VSP_018031;
CC       Name=4;
CC         IsoId=Q6XUX3-4; Sequence=VSP_018030, VSP_018032, VSP_018033;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in skeletal muscle and
CC       testis. Expressed in basolateral and apical membranes of all tubular
CC       epithelia. Expressed in thin ascending limb of the loop of Henle and
CC       the distal convoluted tubule. Expressed in all layers of transitional
CC       ureteric epithelium and in the ureteric smooth-muscle cells. Weakly
CC       expressed in heart, brain, placenta, kidney, pancreas, spleen, thymus,
CC       prostate, uterus, small intestine, white blood cells, stomach, spinal
CC       cord and adrenal gland. Is widely distributed in the CNS. Also detected
CC       in several tumor cell lines. Expressed in the skin (PubMed:28157540).
CC       {ECO:0000269|PubMed:15178406, ECO:0000269|PubMed:17123648,
CC       ECO:0000269|PubMed:23862974, ECO:0000269|PubMed:28157540}.
CC   -!- DISEASE: Congenital anomalies of the kidney and urinary tract 1
CC       (CAKUT1) [MIM:610805]: A disorder encompassing a broad spectrum of
CC       renal and urinary tract malformations that include renal agenesis,
CC       kidney hypodysplasia, multicystic kidney dysplasia, duplex collecting
CC       system, posterior urethral valves and ureter abnormalities. Congenital
CC       anomalies of kidney and urinary tract are the commonest cause of
CC       chronic kidney disease in children. {ECO:0000269|PubMed:23862974}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Spastic paraplegia 23, autosomal recessive (SPG23)
CC       [MIM:270750]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness and
CC       spasticity of the lower limbs. Rate of progression and the severity of
CC       symptoms are quite variable. Initial symptoms may include difficulty
CC       with balance, weakness and stiffness in the legs, muscle spasms, and
CC       dragging the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body. SPG23 is an autosomal
CC       recessive form characterized by childhood-onset of gait difficulties
CC       and pigmentary abnormalities, including premature graying of the hair
CC       and vitiligo-like or hyperpigmented skin lesions.
CC       {ECO:0000269|PubMed:28157540}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY208850; AAP42418.1; -; mRNA.
DR   EMBL; AY429674; AAS55390.1; -; mRNA.
DR   EMBL; AF068286; AAF65505.1; -; mRNA.
DR   EMBL; AC093422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC048204; AAH48204.1; -; mRNA.
DR   EMBL; BC053627; AAH53627.1; -; mRNA.
DR   EMBL; BC060870; AAH60870.2; -; mRNA.
DR   EMBL; BC072406; AAH72406.1; -; mRNA.
DR   EMBL; BC117411; AAI17412.1; -; mRNA.
DR   EMBL; BC143603; AAI43604.1; -; mRNA.
DR   EMBL; AB007941; BAA32317.1; -; mRNA.
DR   CCDS; CCDS1451.1; -. [Q6XUX3-1]
DR   CCDS; CCDS1452.1; -. [Q6XUX3-2]
DR   RefSeq; NP_056190.1; NM_015375.2. [Q6XUX3-1]
DR   RefSeq; NP_955749.1; NM_199462.2. [Q6XUX3-2]
DR   AlphaFoldDB; Q6XUX3; -.
DR   SMR; Q6XUX3; -.
DR   BioGRID; 117313; 66.
DR   IntAct; Q6XUX3; 23.
DR   STRING; 9606.ENSP00000356130; -.
DR   BindingDB; Q6XUX3; -.
DR   ChEMBL; CHEMBL1908386; -.
DR   DrugCentral; Q6XUX3; -.
DR   GlyGen; Q6XUX3; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q6XUX3; -.
DR   PhosphoSitePlus; Q6XUX3; -.
DR   BioMuta; DSTYK; -.
DR   DMDM; 296434486; -.
DR   EPD; Q6XUX3; -.
DR   jPOST; Q6XUX3; -.
DR   MassIVE; Q6XUX3; -.
DR   MaxQB; Q6XUX3; -.
DR   PaxDb; Q6XUX3; -.
DR   PeptideAtlas; Q6XUX3; -.
DR   PRIDE; Q6XUX3; -.
DR   ProteomicsDB; 67816; -. [Q6XUX3-1]
DR   ProteomicsDB; 67817; -. [Q6XUX3-2]
DR   ProteomicsDB; 67818; -. [Q6XUX3-3]
DR   ProteomicsDB; 67819; -. [Q6XUX3-4]
DR   Antibodypedia; 34564; 186 antibodies from 25 providers.
DR   DNASU; 25778; -.
DR   Ensembl; ENST00000367161.7; ENSP00000356129.3; ENSG00000133059.17. [Q6XUX3-2]
DR   Ensembl; ENST00000367162.8; ENSP00000356130.3; ENSG00000133059.17. [Q6XUX3-1]
DR   Ensembl; ENST00000615388.1; ENSP00000478016.1; ENSG00000133059.17. [Q6XUX3-4]
DR   GeneID; 25778; -.
DR   KEGG; hsa:25778; -.
DR   MANE-Select; ENST00000367162.8; ENSP00000356130.3; NM_015375.3; NP_056190.1.
DR   UCSC; uc001hbw.4; human. [Q6XUX3-1]
DR   CTD; 25778; -.
DR   DisGeNET; 25778; -.
DR   GeneCards; DSTYK; -.
DR   HGNC; HGNC:29043; DSTYK.
DR   HPA; ENSG00000133059; Low tissue specificity.
DR   MalaCards; DSTYK; -.
DR   MIM; 270750; phenotype.
DR   MIM; 610805; phenotype.
DR   MIM; 612666; gene.
DR   neXtProt; NX_Q6XUX3; -.
DR   OpenTargets; ENSG00000133059; -.
DR   Orphanet; 101003; Autosomal recessive spastic paraplegia type 23.
DR   Orphanet; 93100; Renal agenesis, unilateral.
DR   PharmGKB; PA164718861; -.
DR   VEuPathDB; HostDB:ENSG00000133059; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00840000129948; -.
DR   HOGENOM; CLU_014116_0_0_1; -.
DR   InParanoid; Q6XUX3; -.
DR   OMA; KSCIHLI; -.
DR   OrthoDB; 254886at2759; -.
DR   PhylomeDB; Q6XUX3; -.
DR   TreeFam; TF331821; -.
DR   PathwayCommons; Q6XUX3; -.
DR   SignaLink; Q6XUX3; -.
DR   BioGRID-ORCS; 25778; 24 hits in 1115 CRISPR screens.
DR   ChiTaRS; DSTYK; human.
DR   GeneWiki; RIPK5; -.
DR   GenomeRNAi; 25778; -.
DR   Pharos; Q6XUX3; Tchem.
DR   PRO; PR:Q6XUX3; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q6XUX3; protein.
DR   Bgee; ENSG00000133059; Expressed in lateral nuclear group of thalamus and 213 other tissues.
DR   Genevisible; Q6XUX3; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell junction; Cell membrane;
KW   Coiled coil; Cytoplasm; Disease variant; Hereditary spastic paraplegia;
KW   Kinase; Membrane; Neurodegeneration; Nucleotide-binding;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..929
FT                   /note="Dual serine/threonine and tyrosine protein kinase"
FT                   /id="PRO_0000233118"
FT   DOMAIN          652..906
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          189..215
FT                   /evidence="ECO:0000255"
FT   COILED          395..431
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        777
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         658..666
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         681
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   VAR_SEQ         1..539
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_018030"
FT   VAR_SEQ         451..792
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018031"
FT   VAR_SEQ         703..718
FT                   /note="SLPKHERLVDLHGSVI -> WVLASFISMRKIQRRI (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_018032"
FT   VAR_SEQ         719..929
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_018033"
FT   VAR_SEQ         824..868
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018034"
FT   VARIANT         29
FT                   /note="R -> Q (in CAKUT1; unknown pathological
FT                   significance; dbSNP:rs200780796)"
FT                   /evidence="ECO:0000269|PubMed:23862974"
FT                   /id="VAR_071324"
FT   VARIANT         200
FT                   /note="D -> G (in CAKUT1)"
FT                   /evidence="ECO:0000269|PubMed:23862974"
FT                   /id="VAR_071325"
FT   VARIANT         432
FT                   /note="L -> V (in dbSNP:rs35845538)"
FT                   /id="VAR_057101"
FT   VARIANT         843
FT                   /note="S -> L (in CAKUT1; dbSNP:rs778586547)"
FT                   /evidence="ECO:0000269|PubMed:23862974"
FT                   /id="VAR_071326"
FT   MUTAGEN         681
FT                   /note="K->Q: No change."
FT                   /evidence="ECO:0000269|PubMed:15178406"
FT   CONFLICT        247
FT                   /note="V -> A (in Ref. 4; AAH72406)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        449
FT                   /note="G -> R (in Ref. 4; AAH60870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        641
FT                   /note="C -> R (in Ref. 1; AAP42418/AAS55390, 2; AAF65505,
FT                   4; AAH53627/AAH72406/AAI17412/AAI43604 and 5; BAA32317)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   929 AA;  105206 MW;  8DDAAC289DE21EE7 CRC64;
     MEGDGVPWGS EPVSGPGPGG GGMIRELCRG FGRYRRYLGR LRQNLRETQK FFRDIKCSHN
     HTCLSSLTGG GGAERGPAGD VAETGLQAGQ LSCISFPPKE EKYLQQIVDC LPCILILGQD
     CNVKCQLLNL LLGVQVLPTT KLGSEESCKL RRLRFTYGTQ TRVSLALPGQ YELVHTLVAH
     QGNWETIPEE DLEVQENNED AAHVLAELEV TMHHALLQEV DVVVAPCQGL RPTVDVLGDL
     VNDFLPVITY ALHKDELSER DEQELQEIRK YFSFPVFFFK VPKLGSEIID SSTRRMESER
     SPLYRQLIDL GYLSSSHWNC GAPGQDTKAQ SMLVEQSEKL RHLSTFSHQV LQTRLVDAAK
     ALNLVHCHCL DIFINQAFDM QRDLQITPKR LEYTRKKENE LYESLMNIAN RKQEEMKDMI
     VETLNTMKEE LLDDATNMEF KDVIVPENGE PVGTREIKCC IRQIQELIIS RLNQAVANKL
     ISSVDYLRES FVGTLERCLQ SLEKSQDVSV HITSNYLKQI LNAAYHVEVT FHSGSSVTRM
     LWEQIKQIIQ RITWVSPPAI TLEWKRKVAQ EAIESLSASK LAKSICSQFR TRLNSSHEAF
     AASLRQLEAG HSGRLEKTED LWLRVRKDHA PRLARLSLES CSLQDVLLHR KPKLGQELGR
     GQYGVVYLCD NWGGHFPCAL KSVVPPDEKH WNDLALEFHY MRSLPKHERL VDLHGSVIDY
     NYGGGSSIAV LLIMERLHRD LYTGLKAGLT LETRLQIALD VVEGIRFLHS QGLVHRDIKL
     KNVLLDKQNR AKITDLGFCK PEAMMSGSIV GTPIHMAPEL FTGKYDNSVD VYAFGILFWY
     ICSGSVKLPE AFERCASKDH LWNNVRRGAR PERLPVFDEE CWQLMEACWD GDPLKRPLLG
     IVQPMLQGIM NRLCKSNSEQ PNRGLDDST
//
